Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Recursion And Exscientia Announce Definitive Agreement To Combine Capabilities For Leading End-To-End Drug Discovery Platform

Author: Benzinga Newsdesk | August 08, 2024 07:40am

Expect 10 Clinical Readouts In 18 Months, $200M In Milestone Payments Over 24 Months, $20B Potentially Overall, $850M Cash On Hand, And $100M Annual Synergies

Posted In: EXAI RXRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist